Trials / Completed
CompletedNCT01695174
A Pilot Study of Xifaxan to Treat Patients With PSC
A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In the current protocol, we propose the assessment of potential beneficial effects of the antibiotic Xifaxan on liver biochemistries, liver related symptoms and Mayo risk score in 15 adult and 5 pediatric patients with PSC. Adult patients will receive Xifaxan, 550 mg twice daily over a 12-week period. Pediatric patients with PSC whose weight is greater than or equal to 40 kg will receive Xifaxan, 550 mg twice daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xifaxan |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-12-01
- Completion
- 2014-03-01
- First posted
- 2012-09-27
- Last updated
- 2014-10-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01695174. Inclusion in this directory is not an endorsement.